Form 8-K CORCEPT THERAPEUTICS For: Jan 28
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Corcept Therapeutics (CORT) Tops Q4 EPS by 3c; Issues Light FY16 Revenue Outlook
January 28, 2016 4:15 PM ESTCorcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.01, $0.03 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $15 million versus the consensus estimate of $15.5 million.
GUIDANCE:
Corcept Therapeutics sees FY2016 revenue of $76-81 million, versus the consensus of... More
